Literature DB >> 30377560

Human CD4- invariant NKT lymphocytes regulate graft versus host disease.

Tereza Coman1,2, Julien Rossignol1,3, Maud D'Aveni4,5,6, Bettina Fabiani7, Michael Dussiot1,8, Rachel Rignault1,8, Joel Babdor1,8, Marie Bouillé1,8, André Herbelin9,10,11, Francine Coté1,8, Ivan C Moura1,8, Olivier Hermine1,3,8, Marie-Thérèse Rubio1,4,5,6.   

Abstract

Despite increasing evidence for a protective role of invariant (i) NKT cells in the control of graft-versus-host disease (GVHD), the mechanisms underpinning regulation of the allogeneic immune response in humans are not known. In this study, we evaluated the distinct effects of human in vitro expanded and flow-sorted human CD4+ and CD4- iNKT subsets on human T cell activation in a pre-clinical humanized NSG mouse model of xenogeneic GVHD. We demonstrate that human CD4- but not CD4+ iNKT cells could control xenogeneic GVHD, allowing significantly prolonged overall survival and reduced pathological GVHD scores without impairing human T cell engraftment. Human CD4- iNKT cells reduced the activation of human T cells and their Th1 and Th17 differentiation in vivo. CD4- and CD4+ iNKT cells had distinct effects upon DC maturation and survival. Compared to their CD4+ counterparts, in co-culture experiments in vitro, human CD4- iNKT cells had a higher ability to make contacts and degranulate in the presence of mouse bone marrow-derived DCs, inducing their apoptosis. In vivo we observed that infusion of PBMC and CD4- iNKT cells was associated with decreased numbers of splenic mouse CD11c+ DCs. Similar differential effects of the iNKT cell subsets were observed on the maturation and in the induction of apoptosis of human monocyte-derived dendritic cells in vitro. These results highlight the increased immunosuppressive functions of CD4- versus CD4+ human iNKT cells in the context of alloreactivity, and provide a rationale for CD4- iNKT selective expansion or transfer to prevent GVHD in clinical trials.

Entities:  

Keywords:  Allogeneic stem cell transplantation; NSG mice; dendritic cells; graft-versus-host disease; human invariant NKT cells; immunoregulation

Year:  2018        PMID: 30377560      PMCID: PMC6204997          DOI: 10.1080/2162402X.2018.1470735

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  41 in total

Review 1.  Pathophysiology of graft-versus-host disease.

Authors:  James L M Ferrara; Pavan Reddy
Journal:  Semin Hematol       Date:  2006-01       Impact factor: 3.851

2.  Limited correlation between human thymus and blood NKT cell content revealed by an ontogeny study of paired tissue samples.

Authors:  Stuart P Berzins; Andrew D Cochrane; Daniel G Pellicci; Mark J Smyth; Dale I Godfrey
Journal:  Eur J Immunol       Date:  2005-05       Impact factor: 5.532

3.  IFN-gamma-mediated prevention of graft-versus-host disease: pharmacodynamic studies and influence on proliferative capacity of chimeric spleen cells.

Authors:  H P Brok; J M Vossen; P J Heidt
Journal:  Bone Marrow Transplant       Date:  1998-11       Impact factor: 5.483

4.  Increased Foxp3+Helios+ Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells.

Authors:  Yi-Bin Chen; Yvonne A Efebera; Laura Johnston; Edward D Ball; David Avigan; Lazaros J Lekakis; Carlos R Bachier; Paul Martin; Omar Duramad; Yasuyuki Ishii; Semi Han; Yu-Jin Jung; Dana Lee; Lori Kunkel; Robert S Negrin; Jack D Bui
Journal:  Biol Blood Marrow Transplant       Date:  2017-01-16       Impact factor: 5.742

5.  Ex-vivo analysis of human natural killer T cells demonstrates heterogeneity between tissues and within established CD4(+) and CD4(-) subsets.

Authors:  A C Chan; E Leeansyah; A Cochrane; Y d'Udekem d'Acoz; D Mittag; L C Harrison; D I Godfrey; S P Berzins
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

6.  Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival.

Authors:  Marie-Thérèse Rubio; Lucia Moreira-Teixeira; Emmanuel Bachy; Marie Bouillié; Pierre Milpied; Tereza Coman; Felipe Suarez; Ambroise Marcais; David Sibon; Agnès Buzyn; Sophie Caillat-Zucman; Marina Cavazzana-Calvo; Bruno Varet; Michel Dy; Olivier Hermine; Maria Leite-de-Moraes
Journal:  Blood       Date:  2012-06-22       Impact factor: 22.113

7.  CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells.

Authors:  Dominik Schneidawind; Antonio Pierini; Maite Alvarez; Yuqiong Pan; Jeanette Baker; Corina Buechele; Richard H Luong; Everett H Meyer; Robert S Negrin
Journal:  Blood       Date:  2014-10-07       Impact factor: 22.113

8.  Third-party CD4+ invariant natural killer T cells protect from murine GVHD lethality.

Authors:  Dominik Schneidawind; Jeanette Baker; Antonio Pierini; Corina Buechele; Richard H Luong; Everett H Meyer; Robert S Negrin
Journal:  Blood       Date:  2015-03-20       Impact factor: 22.113

9.  Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining.

Authors:  Jenny E Gumperz; Sachiko Miyake; Takashi Yamamura; Michael B Brenner
Journal:  J Exp Med       Date:  2002-03-04       Impact factor: 14.307

Review 10.  Invariant Natural Killer T Cells As Suppressors of Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Melissa Mavers; Kristina Maas-Bauer; Robert S Negrin
Journal:  Front Immunol       Date:  2017-07-31       Impact factor: 7.561

View more
  11 in total

1.  High-parametric evaluation of human invariant natural killer T cells to delineate heterogeneity in allo- and autoimmunity.

Authors:  Tom Erkers; Bryan J Xie; Laura J Kenyon; Brian Smith; Mary Rieck; Kent P Jensen; Xuhuai Ji; Marina Basina; Samuel Strober; Robert S Negrin; Holden T Maecker; Everett H Meyer
Journal:  Blood       Date:  2020-03-12       Impact factor: 22.113

Review 2.  An Unconventional View of T Cell Reconstitution After Allogeneic Hematopoietic Cell Transplantation.

Authors:  Hana Andrlová; Marcel R M van den Brink; Kate A Markey
Journal:  Front Oncol       Date:  2021-02-18       Impact factor: 6.244

3.  Invariant natural killer T-cell subsets have diverse graft-versus-host-disease-preventing and antitumor effects.

Authors:  Kristina Maas-Bauer; Juliane K Lohmeyer; Toshihito Hirai; Teresa Lopes Ramos; Furqan M Fazal; Ulrike M Litzenburger; Kathryn E Yost; Jessica V Ribado; Neeraja Kambham; Arielle S Wenokur; Po-Yu Lin; Maite Alvarez; Melissa Mavers; Jeanette Baker; Ami S Bhatt; Howard Y Chang; Federico Simonetta; Robert S Negrin
Journal:  Blood       Date:  2021-09-09       Impact factor: 25.476

4.  Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model.

Authors:  Céline Grégoire; Caroline Ritacco; Muriel Hannon; Laurence Seidel; Loïc Delens; Ludovic Belle; Sophie Dubois; Sophie Vériter; Chantal Lechanteur; Alexandra Briquet; Sophie Servais; Gregory Ehx; Yves Beguin; Frédéric Baron
Journal:  Front Immunol       Date:  2019-04-02       Impact factor: 7.561

Review 5.  Seeking biomarkers for acute graft-versus-host disease: where we are and where we are heading?

Authors:  Xiao-Su Zhao; Xiao-Jun Huang
Journal:  Biomark Res       Date:  2019-08-07

Review 6.  Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma.

Authors:  Darel Martínez Bedoya; Valérie Dutoit; Denis Migliorini
Journal:  Front Immunol       Date:  2021-03-03       Impact factor: 7.561

7.  Invariant NKT cells as a platform for CAR immunotherapy and prevention of acute Graft-versus-Host Disease.

Authors:  Anastasios Karadimitris; Carme Ripoll-Fiol; Jose Costa Guerra
Journal:  Hemasphere       Date:  2019-06-30

Review 8.  How to Make an Immune System and a Foreign Host Quickly Cohabit in Peace? The Challenge of Acute Graft-Versus-Host Disease Prevention After Allogeneic Hematopoietic Cell Transplantation.

Authors:  Benoît Vandenhove; Lorenzo Canti; Hélène Schoemans; Yves Beguin; Frédéric Baron; Carlos Graux; Tessa Kerre; Sophie Servais
Journal:  Front Immunol       Date:  2020-10-21       Impact factor: 7.561

Review 9.  iNKT: A new avenue for CAR-based cancer immunotherapy.

Authors:  Yilin Liu; Gang Wang; Dafei Chai; Yuanyuan Dang; Junnian Zheng; Huizhong Li
Journal:  Transl Oncol       Date:  2022-01-18       Impact factor: 4.243

10.  Human invariant natural killer T cells promote tolerance by preferential apoptosis induction of conventional dendritic cells.

Authors:  Hannes Schmid; Emmanuelle M Ribeiro; Kathy-Ann Secker; Silke Duerr-Stoerzer; Hildegard Keppeler; Ruoyun Dong; Timo Munz; Klaus Schulze-Osthoff; Stephan Hailfinger; Corina Schneidawind; Dominik Schneidawind
Journal:  Haematologica       Date:  2022-02-01       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.